Intra Cellular Therapies traded at $56.17 this Wednesday July 6th, decreasing $0.92 or 1.61 percent since the previous trading session. Looking back, over the last four weeks, Intra Cellular Therapies lost 4.46 percent. Over the last 12 months, its price rose by 37.00 percent. Looking ahead, we forecast Intra Cellular Therapies to be priced at 53.67 by the end of this quarter and at 49.43 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
ALKERMES 31.87 0.44 1.40% 25.03%
Aptinyx Inc 0.57 0.04 7.51% -79.04%
BioCryst Pharmaceuticals 11.23 0.09 0.81% -29.33%
Biogen 217.17 1.19 0.55% -41.15%
Bristol-Myers Squibb 75.82 -0.40 -0.52% 13.69%
Cytokinetics 44.14 0.24 0.55% 123.27%
Esperion Therapeutics 6.69 -0.30 -4.29% -65.25%
Gilead Sciences 62.58 -0.15 -0.24% -7.55%
Halozyme Therapeutics 46.75 0.42 0.91% 2.48%
Intra Cellular Therapies 56.17 -0.92 -1.61% 37.00%
Jazz Pharmaceuticals 160.44 0.40 0.25% -12.81%
J&J 178.42 0.12 0.07% 5.52%
Marinus Pharmaceuticals 4.77 -0.25 -4.98% -74.56%
Neurocrine Biosciences 95.20 -3.10 -3.15% -3.05%
Minerva Neurosciences 3.21 -0.04 -1.23% 38.96%
Nektar Therapeutics 3.90 -0.03 -0.76% -76.53%
Novartis 83.73 -0.55 -0.65% -8.93%
Prothena 30.09 0.49 1.66% -45.51%
RedHill Biopharma 0.93 0.01 1.16% -85.28%
Supernus Pharmaceuticals 30.50 0.70 2.35% 4.88%
United Therapeutics 241.90 4.75 2.00% 29.37%
Vanda Pharmaceuticals 11.69 0.19 1.65% -42.10%

Indexes Price Day Year
USND 11417 55.27 0.49% -21.58%
US2000 1743 15.15 0.88% -21.91%

Intra Cellular Therapies
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.